Vaccine Strategy faculty

The need for a Vaccine strategy for the Ebola belt of Africa.

The Vaccine Strategy faculty Members

Leading vaccine contenders, Safety Profile and. Clinical Trials.

Charles Shey Wiysonge
Charles is a Professor of Clinical Epidemiology and Deputy Director of the Centre for Evidence-based Health Care, Stellenbosch University, South Africa; and a Chief Specialist Scientist at Cochrane South Africa, South African Medical Research Council. He previously served as Manager of the Vaccines for Africa Initiative and Chief Research Officer at the University of Cape Town, South Africa; Chief Research Officer at UNAIDS, Geneva; and Deputy Director, National Expanded Programme on Immunisation, Cameroon.

Charles holds an MD from the University of Yaoundé I (Cameroon), an MPhil from the University of Cambridge (UK), and a PhD from the University of Cape Town (South Africa). He also undertook postgraduate training at the UK Cochrane Centre and the University of Oxford, UK. In addition, Charles is a Member of the Academy of Science of South Africa.

Charles was a member of the African Task Force on Immunisation (now known as the African Regional Immunisation Technical Advisory Group) from 2013 to 2015. In addition, he is a member of the Strategic Advisory Group of Experts on Immunisation (SAGE); the SAGE Working Group on Ebola Vaccines and Vaccination; the SAGE Working Group on Maternal and Neonatal Tetanus Elimination and Broader Tetanus Control; the SAGE Methodology Group; the Evidence Based Recommendations Work Group, US Advisory Committee on Immunization Practices (ACIP); the Independent Review Committee of Gavi, The Vaccine Alliance; the Grading of Recommendations Assessment, Development and Evaluation (GRADE) Working Group; and the executive committee of the GREAT (Guideline‐driven, Research priorities, Evidence synthesis, Application of evidence, and Transfer of knowledge) Network.
Charles conducts research on childhood immunisation, systematic reviews, and knowledge translation.

Paul D. Hodgson, PhD., MBA

Dr. Hodgson has been a member of the senior leadership team at the University of Saskatchewan’s Vaccine and Infectious Disease Organization-International Vaccine Centre (VIDO-InterVac) for the past decade. He is responsible for business development, strategic planning, marketing and communications.

Prior to joining VIDO-InterVac, Paul managed several multi-million dollar projects funded by Genome Canada and the Bill and Melinda Gates Foundation and helped establish Newfound Genomics prior to its acquisition by Sequenom.  In addition to his role at VIDO-InterVac Paul is a member of Canada’s Vaccine Industry Committee and a founding Director and the Corporate Secretary of the Pan-Provincial Vaccine Enterprise Inc – a company focused on accelerating vaccine development for diseases of major public health concern.  From a community perspective he is a past Chair of the Science and Technology campaign for the United Way in Saskatoon and is a past Chair of the Board for Big Brothers, Big Sisters of Saskatoon and Area, where he remains as an Ambassador to the organization.

A native of Toronto, Canada Paul received his BSc and MSc in Pharmacology from Dalhousie University, his PhD in Medicine from Memorial University and his MBA from the University of Alberta.

Stephen B. Kennedy, MD, MPH, is trained in general medicine, infectious disease biomedical research, infectious disease epidemiology and international health from Liberia, United States (U.S.) and Zambia. Dr. Kennedy possesses nearly 2 decades of experience in public health, prevention research, biomedical and clinical-based research, and clinical trials in HIV/AIDS, STDs, Malaria, Tuberculosis (TB), community health, and Ebola Virus Disease (EVD). Furthermore, Dr. Kennedy possesses nearly 3 decades of experience as a medical doctor in Sub-Saharan Africa.

Presently, Dr. Kennedy serves as Coordinator for EVD Research at the Liberia’s Emergency Operations Center (EoC) of the Incident Management System (IMS) of the Ministry of Health (MoH), Liberia’s PI for the EVD Vaccine Clinical Trial of the Liberia-US Joint Clinical Research Partnership of the Partnership for Research on Ebola Vaccines in Liberia (PREVAIL), Co-PI for a three-country EVD Vaccine Clinical Trial (PREVAC) of a multinational (NIH, INSERM, LSHTM) and most affected countries (Sierra Leone, Guinea & Liberia) consortium, Associate Co-PI for EVD therapeutic trial among male EVD survivors in Liberia, thematic Lead for the establishment of biobank in Liberia, Lead for Research & Capacity Enhancement for the West African Taskforce for the Control of Emerging and Re-emerging Infectious Diseases (WATER), Member of the Core Working Group (CWG) of the Sub-Regional Collaboration Research Group on EVD Vaccines and Therapeutics, and member of the Action Committee on Viral Hemorrhagic Fevers (VHFs), including Lassa Fevers (LFs) and EVDs, for the West Africa College of Physicians (WACP), respectively.

Lastly, Dr. Kennedy is Fellow of the Liberia College of Physicians (FLCP) and Fellow of the West African College of Physicians (FWACP).

Wilson Mok has been with the Gavi Secretariat since 2013. He currently serves as a Strategy Specialist in the Policy & Market Shaping team. At the Secretariat, he has worked on a range of policy and strategy projects. This includes serving as the market shaping focal point and developing strategies for several Gavi portfolio vaccines. He has also overseen the development of a policy to provide countries transitioning out of Gavi support with continued access to appropriate vaccine pricing. His current responsibilities include leading initiatives regarding Gavi’s role in outbreak preparedness and response.

Prior to his work at the Gavi Secretariat, Wilson served as a strategy consultant for the HIV team at the Bill & Melinda Gates Foundation, focusing on antiretroviral-based prevention. He also served as a management consultant in the healthcare sector with McKinsey & Co., where he advised vaccine manufacturers and other pharmaceutical and healthcare companies. Wilson is a chemical engineer by training, receiving his undergraduate degree from UC Berkeley and his PhD from the Massachusetts Institute of Technology.

Dr Moussa Doumbia is from Mali, I am physician, have been working at Center for Vaccines Development-Mali since 2001. Currently I am working for WHO on the Ebola clinical vaccine trial in Guinea (Guinea Ring Vaccination) as Principal Investigator

Oyekanmi Nash, PhD is the Director, Genetics, Genomics and Bioinformatics at the National Biotechnology Development Agency (NABDA), Abuja, Nigeria. He’s also the Director (Africa) for the International Consortium on Anti-Virals, ICAV. He’s the PI of the NABDA Node for the H3Africa Bioinformatics Network (H3ABioNet).  He’s currently coordinating the Nigeria/China Vaccine Initiative (NCVI)

Dr. Callendret expertise encompasses virology, immunology and vaccine development. Dr. Callendret received his DVM degree from the National Veterinary School in Toulouse in 2002 focusing on with bovine respiratory syncytial virus. He obtained his Ph.D. in 2007 working on the development of vaccines against Severe Acute Respiratory Syndrome (SARS) coronavirus in collaboration with GlaxoSmithKline at the Institut Pasteur in Paris, using both viral vectors and recombinant subunit vaccines approaches.

His postdoctoral training explored the mechanisms of viral escape from immune pressure imposed by cytotoxic lymphocytes during chronic hepatitis C virus (HCV) infection and innovative strategies for therapeutic vaccination against chronic HCV infection combining active immunization, immunomodulators and antiviral drugs.

Dr. Callendret joined Janssen Vaccines & Prevention in 2012 to lead the preclinical development of the multivalent filovirus vaccine program in close interaction with the Division of Microbiology and Infectious Disease and the Joint Vaccine Acquisition Program. Since 2014, Dr. Callendret is acting as Compound Development Team Leader of Janssen monovalent Ebola vaccine program, and he recently took on the Compound Development Team Leader role for the Multivalent Filovirus vaccine program.

Dr Toritse Orubu is currently the Director of Innovation & Emerging Markets, Vaccines & Innovation for Global Health, Seattle, USA. At VIGH, he provides technical guidance on investment strategies to pharmaceutical companies, biotech and academic institutions on novel technologies for manufacturing and deploying vaccines in emerging markets.

Dr. Orubu recently completed a 2-year fellowship for Vaccines Development (CMC) at the Bill and Melinda Gates Foundation. He joined the Foundation with more than 15 years’ experience in public health and vaccine research and development.

At the Bill and Melinda Gates Foundation, Dr. Orubu provided technical guidance and strategic support across teams on innovative technologies for reducing cost of vaccine manufacturing, including application of novel devices and technologies for deployment of vaccines in resource poor countries. He also led the foundation’s novel combination and heat stable vaccine strategy.

Prior to joining the Foundation, Dr. Orubu was a Senior Manager, New Vaccine Introduction at the Clinton Health Access Initiative (CHAI). In this role, he managed CHAI’s work on the successful introduction of pentavalent vaccines to over 8 million children in Nigeria.

Dr. Orubu has also worked with the Family Health International (FHI 360), Nigeria Academy of Science and the Carter Center for Global Guinea Worm Eradication. He has a multi-disciplinary background in vaccines, immunizations, public health, infectious diseases, diagnostics, devices, technology innovation, health systems, policy, business planning and development.

Dr. Orubu holds a BSc in Microbiology from the University of Benin (Benin City, Nigeria), a post-graduate diploma and MSc in Immunology of Infectious Diseases from the London School of Hygiene and Tropical Medicine (London, United Kingdom), a MSc in Public Health (MPH) from the University of Aberdeen (Scotland, United Kingdom) and a doctorate degree in Vaccinology from the University of Oxford (England, United Kingdom). At Oxford, he focused on developing recombinant pox viral vaccines (MVA) against malaria infection and was also a GSK Fellow at the Jenner Institute, University of Oxford, where he worked on heat stable vaccines.

Dr .IBRAHIM MAMAN SANI Ismaila worked as study medical officer, then medical coordinator during the phase three WHO Randomized clinical vaccine trial in Guinea and Sierra Leon during the outbreak. Also has been leading the 2 compassionate use the vaccine (VSV-Zebov) for the last Ebola cases in Sierra Leon and Guinea after the end of the epidemic. He is currently working as Co-Principal Investigator in the phase two WHO vaccine trial in Guinea working on the immunogenicity, using two cohort (survivors’ body fluid sample collection and contact vaccination plus swab and blood samples collection).
He has worked in the Wonkifong ETU as ASEOWA/AU direct volunteer clinicians Team leader, after working as emergency doctor in the emergency units of the National Hospital of Niamey (Niger Rep) then of the Teaching hospital of Lamorde in Niamey (Niger Rep).

Dr. Mark Kieh worked as a Site Physician for the Randomized Clinical Trial of Ebola Vaccine in Liberia. He has been instrumented in the implementation and supervision of the conduct of the trial. He is currently working in the planning and design of a three nation clinical trial of Ebola vaccines in the three affected countries, namely, Guinea, Liberia, and Sierra Leone.

He has worked as a clinical coordinator at the clinical department of the Liberia Medical and Dental Association, a regulatory body, which supervises the conduct of medical practitioners in the practice of medicine in Liberia.